Targeted therapy plus chemo for lymphoma that has spread to the brain
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 80 years old.
- You must have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL).
- This study is for lymphoma that has spread to the brain or spinal cord (called CNS involvement), which can be confirmed by symptoms, imaging, or lab tests.
- Your bone marrow, liver, kidney, and blood counts must meet certain levels (your doctor will check).
- If you have had other treatments, most side effects must have gotten much better.
- Women who can become pregnant and men who can father children must use effective birth control during the trial and for 3 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hear when a new Pirtobrutinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.